NEROFE
An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 18 patients (estimated)
- Sponsors
- Immune System Key Ltd
- Collaborators
- Sylvester Comprehensive Cancer Center (Main)
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1595
- NCT Identifier
- NCT04365179
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.